Vanguard Personalized Indexing Management LLC Invests $51,000 in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 31,423 shares of the biotechnology company’s stock, valued at approximately $51,000.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its holdings in Atara Biotherapeutics by 1.3% in the 1st quarter. BlackRock Inc. now owns 9,271,298 shares of the biotechnology company’s stock worth $26,887,000 after purchasing an additional 119,149 shares in the last quarter. Baupost Group LLC MA increased its holdings in Atara Biotherapeutics by 12.3% in the 1st quarter. Baupost Group LLC MA now owns 9,123,616 shares of the biotechnology company’s stock worth $26,458,000 after purchasing an additional 1,000,000 shares in the last quarter. State Street Corp increased its holdings in Atara Biotherapeutics by 7.7% in the 1st quarter. State Street Corp now owns 8,237,473 shares of the biotechnology company’s stock worth $23,889,000 after purchasing an additional 587,733 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Atara Biotherapeutics by 2.1% in the 1st quarter. JPMorgan Chase & Co. now owns 7,655,769 shares of the biotechnology company’s stock worth $22,201,000 after purchasing an additional 156,334 shares in the last quarter. Finally, Wasatch Advisors Inc. increased its holdings in Atara Biotherapeutics by 88.8% in the 1st quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock worth $35,521,000 after purchasing an additional 1,798,072 shares in the last quarter. Institutional investors and hedge funds own 88.79% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ATRA shares. StockNews.com started coverage on Atara Biotherapeutics in a report on Thursday, October 5th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, September 26th.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock opened at $1.25 on Friday. Atara Biotherapeutics, Inc. has a 52-week low of $1.24 and a 52-week high of $5.64. The firm has a 50 day moving average price of $1.51 and a two-hundred day moving average price of $1.90. The firm has a market cap of $126.38 million, a price-to-earnings ratio of -0.43 and a beta of 1.00.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.03). Atara Biotherapeutics had a negative return on equity of 315.45% and a negative net margin of 4,437.45%. The firm had revenue of $0.96 million for the quarter, compared to the consensus estimate of $3.36 million. As a group, equities research analysts predict that Atara Biotherapeutics, Inc. will post -2.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 30,766 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $1.65, for a total transaction of $50,763.90. Following the completion of the transaction, the chief executive officer now owns 675,905 shares in the company, valued at approximately $1,115,243.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 47,624 shares of company stock worth $78,580. 4.50% of the stock is currently owned by insiders.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.